Other cholesterol-lowering drugs, such as proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, seem to potentiate immune checkpoint therapy in cancer patients [45] and might even be used as a potential future therapeutic target in personalized cancer medicine [46]. The gene discussed is PCSK9; the disease is cancer.